Beacon Pointe Advisors’s Aquestive Therapeutics AQST Stock Holding History

Beacon Pointe Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$252K	Hold	60,500	–	–	﹤0.01%	1706
2026 Q1	$251K	Buy	+60,500	New	+$246K	﹤0.01%	1632
2025 Q3	–	Sell	-60,000	Closed	-$199K	–	1386
2025 Q2	$199K	Hold	60,000	–	–	﹤0.01%	1192
2025 Q1	$174K	Hold	60,000	–	–	﹤0.01%	1164
2024 Q4	$214K	Hold	60,000	–	–	﹤0.01%	1127
2024 Q3	$299K	Hold	60,000	–	–	﹤0.01%	1024
2024 Q2	$156K	Hold	60,000	–	–	﹤0.01%	1205
2024 Q1	$256K	Hold	60,000	–	–	﹤0.01%	1162
2023 Q4	$121K	Hold	60,000	–	–	﹤0.01%	1266
2023 Q3	$91.8K	Hold	60,000	–	–	﹤0.01%	1288
2023 Q2	$99K	Buy	+60,000	New	+$109K	﹤0.01%	1050
2023 Q1	–	Sell	-60,000	Closed	-$54.1K	–	1143
2022 Q4	$54.1K	Hold	60,000	–	–	﹤0.01%	1039
2022 Q3	$70K	Hold	60,000	–	–	﹤0.01%	972
2022 Q2	$38K	Buy	+60,000	New	+$79.8K	﹤0.01%	1028

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Beacon Pointe Advisors's AQST Position: Q2 2026 in Review

Beacon Pointe Advisors held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 60,500 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Beacon Pointe Advisors first reported a position in AQST in Q2 2022 and has held it in 14 quarters since. The position peaked at $299K in Q3 2024. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Beacon Pointe Advisors held 60,500 shares of Aquestive Therapeutics worth $252K as of Q2 2026.
Beacon Pointe Advisors left its Aquestive Therapeutics share count unchanged in Q2 2026.
Aquestive Therapeutics made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1706 holding.
Beacon Pointe Advisors first reported a position in Aquestive Therapeutics in Q2 2022 and has held it in 14 quarters since.
Beacon Pointe Advisors's Aquestive Therapeutics position peaked at $299K in Q3 2024.
184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.